Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

UK Price Scheme Changes To Cost Pharmaceutical Industry £33m

The government is expecting to reap UK-wide savings of £33m by basing the statutory drug pricing scheme on regular payments on sales rather than price cuts and limiting the maximum prices companies can charge the NHS. The move will bring the scheme more into line with the voluntary PPRS.

Pricing Debate Policy & Regulation United Kingdom

US FDA Pushes Back On Proposal For Early Clinical Designations To Support Higher Reimbursement Decisions

Breakthrough, RMAT designations signal clinical potential and are not intended to have reimbursement impact after approval, FDA says. 
Review Pathway Reimbursement Policy

Opioid Spotlight: Trump Announces Plans For More Spending As Congress Introduces Two Dozen Bills

Administration also plans to roll out slate of proposals to decrease drug prices and bring discounts to patients.

Legislation Neurology Legal Issues

Long Serving Deputy Becomes China Health Commissioner

China's third-ranked health official Ma Xiaowei has been promoted to the top position, leading an agency transforming itself from treating diseases to health policy-making against a backdrop of a fast-aging population, emerging data and new AI technologies.

Appointments Asia Pacific China

FDA Performance Tracker

Keeping Track: A Burst Of Breakthroughs, A Priority Review For Keytruda, And Some Supplemental Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation United States

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Patient Experience Data: Industry Seeks US FDA Clarity On Submission Pathway And Labeling

Dedicated mechanism may be needed for biopharma sponsors and patient advocacy groups to talk to agency about patient experience data collection and analysis; industry wants FDA to clarify where such data will appear in product labeling, while advocates ask agency to be mindful of limited resources many patient groups have for conducting such research.

Drug Approval Standards Rare Diseases FDA

Latest From Regulation

Drug Safety: Sequential Surveillance Helps Regulatory Decision-Making, But Hurt By Premature Specification

US FDA and academic researchers say unknowns related to certain product aspects make it difficult to form a hypothesis in formal sequential surveillance designs.
Drug Safety Post Market Regulation & Studies

IND Safety Reporting: Stakeholders Tussle Over Which Adverse Events To Report, Proper Oversight Body

US FDA officials, drug sponsors discussing creation of library of adverse event rates.

Drug Safety Regulation

GSK Adds £50m Per Year To Brexit Cost Estimates

Brexit is likely to cost GSK around £50m a year in the form of customs duties and transaction and administration costs. It is one of a handful of companies to have made its cost estimates public.

Brexit Regulation

Latest From Policy

One-Third Of Payers Preferred Biosimilars Over Reference Drug in 2017

As biosimilar uptake remains modest, rebate amounts trend upward for medical benefit drugs, according to latest MagellanRx drug trend report.

Biosimilars Pricing Strategies

Shire, Microsoft and Eurordis Partner To Improve Diagnosis And Treatments For Rare Disease

An alliance between Shire, Eurordis and Microsoft to speed up diagnosis of rare diseases in children could lead to better access to treatments and the development of new medicines.

Market Access Policy

340B Hospitals May Be Losing Transparency Debate In Congress

Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.

Pricing Debate Legislation

Clinical / R&D Explore this Topic

Set Alert for Clinical R&D

Latest From Research & Development

Right-To-Try Bill In House Limits Process To Patients Facing 'Severely Premature Death'

Vote slated for Tuesday; legislation is somewhat narrower than Senate-passed bill, which applies to patients with a 'life-threatening disease or condition.'

Legislation Clinical Trials

CTI's Approval Prospects For Pacritinib In Myelofibrosis Look To Be Improving

Firm publishes final data from a Phase III study showing the safety-troubled JAK2/FLT3 inhibitor performs better than Jakafi in reducing spleen size. Ongoing dose-finding study will determine the regulatory path forward.

Drug Review Clinical Trials

Tie-Ups, Chronic Diseases Influence Korea Generic Regulatory Patterns

South Korean pharma firms are still heavily dependent on generics for revenues, but approvals for required bioequivalence tests continue to drop, indicating that more developers are opting for joint studies and co-development. By therapeutic area, chronic disease drugs led generic development in the country in 2017 amid an aging population and increasingly Westernized eating habits.

Research & Development Drug Review

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Praluent’s Price Cut: Testing The Tech Model For Drug Pricing

It may be more accident than design, but Sanofi and Regeneron are applying a tried and true pricing model to Praluent. Just ask tech companies. 
Pricing Strategies Cardiovascular

Praluent Pricing: Collaboration With ICER Sets A New Standard

Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.

Pricing Debate Pricing Strategies

Express Scripts Combination With Cigna's PBM Could Reverse Deficit From Losing Anthem

Merger could restore number of covered lives PBM will lose once its contract with Anthem expires, but there is also risk of alienating current health plan clients who don't want to contract with a competitor.

Pharmacy Benefit Management M & A

Manufacturing Explore this Topic

Set Alert for Manufacturing

Latest From Manufacturing

Risk-Based Contamination Limits Suggested For Highly Potent Drugs

As more highly potent and highly toxic drugs are being developed, regulators are looking into risks posed by contamination of non-contact surfaces, yet until recently, there was scant guidance on how to assess these risks.

Europe United States

Why Most Firms Still Don't Use RABS Or Isolators To Better Protect Filling Lines From Contamination

Despite the reduced risk of contaminating sterile drug products, most manufacturers are still not using advanced technologies such as RABS and isolators in the cleanroom. High costs and lack of regulatory pressure were cited in survey responses as reasons for the slow uptake. 
United States Manufacturing

Industry Groups Seek Clarity From FDA On Exception Handling Under DSCSA

As supply chain partners drill down into implementing the last phase of Drug Supply Chain Security Act serialization, they ask FDA for more clarity, and some relief, on exception handling for products with no serial numbers after full track-and-trace goes into effect.
Manufacturing Quality

Consumer / OTC Drugs Explore this Topic

Set Alert for Consumer OTC Drugs

Latest From Consumer

Alka-Seltzer Plus Labeling Error Prompts Recall From Some US Stores

Recall is second in a year for products marketed under the iconic Alka-Seltzer brand. Alka-Seltzer Plus line comprises products indicated for cold alone or for cough/cold; cold and flu and symptoms including sinus pressure, and are available in regular and extra-strength and day and night formulations.
United States Consumer

Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas

Commissioner Gottlieb has been a “very strong champion” of FDA and his interest in improving the OTC monograph and switch processes provides hope to the industry during a tumultuous legislative era, say CHPA executives at their annual meeting in Florida. They expect monograph reform will happen this year but doubt much else will happen before mid-term elections in November.

Prescription To Otc Switch Drug Approval Standards

For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters

OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.

Consumer Prescription To Otc Switch